Immugenia Inc.
PrivateLast Round
Grant
Oct 15, 2024
Company Overview
Immugenia Inc. operates in Healthcare & Life Sciences and is based in Sherbrooke. Its latest recorded funding round was a Pre Seed round in October 2022.
Immugenia Inc. is a biotechnology company that develops immuno-oncology therapies by engineering hematopoietic stem cells to treat cancer and prevent relapses.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immugenia Inc. Comparables
Compare Immugenia Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Allogenica | 84% | |
| Ensoma | 76% | |
| EXUMA Biotech | 73% |
For institutional investors. Book with your work email.
Immugenia Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 15, 2024 | ||||
| Pre Seed | Oct 6, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Immugenia Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Brain Canada Foundation | Grant |
| Consortium Québécois sur la découverte du médicament | Grant |
| Accélérateur de création d'entreprises technologiques | Pre Seed |
| adMare BioInnovations | Pre Seed |
| Sherbrooke Innopole | Pre Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 15, 2024
$3M grant received from Brain Canada Foundation and others.
- Oct 6, 2022
Secured funding from adMare BioInnovations, Accélérateur de création d'entreprises technologiques, and Sherbrooke Innopole.
For institutional investors. Book with your work email.
Immugenia Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Immugenia Inc.'s valuation, stock price, and market status.
Is Immugenia Inc. a public or private company?
Immugenia Inc. is a private company.
What is the current stock price of Immugenia Inc.?
Immugenia Inc. is a private company, so its shares have no public market price. Caplight tracks Immugenia Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Immugenia Inc. worth (valuation)?
Valuation information for Immugenia Inc. is not publicly available.
Can I buy Immugenia Inc. stock?
Immugenia Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Immugenia Inc.'s last funding round?
Immugenia Inc.'s most recent funding round was Grant on October 15, 2024.
Who are the main investors in Immugenia Inc.?
Key investors in Immugenia Inc. include Brain Canada Foundation, Consortium Québécois sur la découverte du médicament, Accélérateur de création d'entreprises technologiques, adMare BioInnovations, Sherbrooke Innopole.
Will Immugenia Inc. IPO soon?
No public IPO plans have been announced for Immugenia Inc..
How can I track Immugenia Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Immugenia Inc.'s shares on secondary markets.